Navigation Links
Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Date:9/5/2007

Very Robust Findings on the Key Problems Faced by Insomniacs, i.e. Sleep Onset and Sleep Maintenance

Evotec to Host a Conference Call Today at 11:00 am CET (10:00 am UK time, 5:00 am EST, 7:00 pm AEST) Directly From the Worldsleep07 Congress in Australia

HAMBURG, Germany and OXFORD, England, September 5 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) presented today at the worldsleep07 congress in Cairns, Australia the details of the results from its first Phase II clinical trial of EVT 201 in patients with primary insomnia. EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. The double-blind, placebo controlled cross-over study of two doses of EVT 201 (1.5mg and 2.5mg) in 67 completed patients was conducted in sleep labs in the US using objective polysomnography (PSG). After having published top-line results in a press release on 4 June 2007, the results of the detailed analysis are herewith reported.

The detailed analysis showed that all endpoints achieved an even higher level of statistical significance than first indicated. The pre-specified intention-to-treat analysis of the study showed that on both of the co-primary endpoints of Total Sleep Time (TST) and Wake After Sleep Onset (WASO) the statistical significance of both doses against placebo was p<0.0001.

Highly statistically and clinically meaningful effects were also found on both the Latency to Persistent Sleep (LPS) and TST in the second half of the night, indicating strong effects on both sleep onset and sleep maintenance. In addition to these objective PSG results, there were highly significant improvements, at both dose levels, on the subjective perception of sleep quality.

The following morning there was no subjective perception of any residual sedation. The Digit Symbol Substitution Test (DSST) showed a small but clinically insignificant change tested the next day 9 h after dosing.

The PSG analysis also showed that EVT 201 did not have a negative impact on sleep architecture unlike many benzodiazepine full agonists.

As in all previous clinical studies, EVT 201 was demonstrated to be safe and well-tolerated at both doses. No serious or unexpected adverse events were reported.

The table below shows the actual results for each of the primary and selected secondary endpoints:

Parameter Placebo EVT 201 EVT 201

N=67 1.5 mg 2.5 mg

Adjusted mean WASO (mins) 47.2 (26%) 38.2 (40%)

63.9 p<0.0001 p<0.0001

Adjusted mean TST (mins) 412 (9%) 424 (12%)

379 p<0.0001 p<0.0001

Adjusted mean LPS (mins) 25.2 (40%) 21.6 (49%)

42.3 p<0.0001 p<0.0001

Adjusted mean Total Wake 32.1 (25%) 26.7 (38%)

Time 2nd half (mins)

42.9 p=0.0008 p<0.0001

Adjusted mean Slow Wave 30.4 (2.4%) 29.9 (0.7%)

Sleep (mins)

29.7 NS NS

Subjective sleep quality 75.2% 78.7%

(very good/good) 41.2 % p<0.0001 p<0.0001

Adjusted mean DSST 56.2 54.3

(number correct) 58.5 p= 0.0028 p<0.0001

Subjective residual

sedation

57.6% 48.0%

(very alert/somewhat

alert in %) 52.6 % NS NS

The large effect size on Total Wake Time (TWT) for the second half of the night indicates that EVT 201 is highly effective in maintaining sleep throughout the night. This was further confirmed by the hour-by-hour analysis of TWT. Although the study was not powered for such an analysis, the reduction in TWT produced by EVT 201 was statistically significant for all hours of the night apart from hour 7 which came very close to reaching statistical significance (p= 0.058).

Commenting on the results, Dr John Kemp, Chief Research & Development Officer, Evotec AG, said: "I'm absolutely delighted with the results of this proof-of-concept Phase II study. The magnitude of effect on sleep maintenance appears more robust than those seen with other agents in similar cross-over design studies. In particular, we are not aware of similar studies that have demonstrated such statistically significant effects on Total Wake Time in the second half of the night and Total Wake Time each hour."

Jorn Aldag, President and Chief Executive Officer, Evotec AG, said: "Although certain aspects of insomnia are addressed by current treatments, there is no drug yet available which meets all the needs of insomnia patients. In our study EVT 201 demonstrated extremely robust findings on all key aspects of the problems faced by insomniacs, i.e. sleep onset and sleep maintenance and yet was without the patients feeling any drug hang-over effects after waking in the morning. We believe this gives EVT 201 a very competitive profile compared to the currently available insomnia treatments and to those in late stage clinical development."

Principal Investigator Dr James Walsh, Executive Director of the Sleep Medicine and Research Center, St John's Mercy Medical Center, Chesterfield, Missouri, US, said: "Due to its partial positive allosteric modulation of GABAA receptors, EVT 201 provides a novel approach to the treatment of insomnia, yet since the GABAA system is a well understood pathway, the risk of unexpected side effect findings are low compared to completely novel mechanisms. This together with robust effect sizes seen in this study, particularly with regard to sleep maintenance, offers considerable promise for the drug as a treatment for insomnia patients."

A second Phase II clinical trial of EVT 201 in elderly patients with primary insomnia for further differentiation is ongoing. Top-line results from this trial are expected to be announced in October 2007.

Webcast Presentation and Conference Call

Evotec will hold a conference call today at 11.00 am CET (10.00 am UK time/05.00 am EST, 07.00 pm AEST) to present details on positive Phase II study in insomnia with EVT 201. Dr John Kemp, Chief Research & Development Officer, and Dr Tim Tasker, Executive Vice President, Clinical Development will lead the call.

Australia: +61-2-8223-9234

Germany: +49-69-9897-2631

UK: +44-20-7138-0814

Switzerland: +41-44-800-9659

US: +1-718-354-1157

Webcast: http://www.evotec.com

The on-demand version of the webcast will be available on our website: http://www.evotec.com - Investors - Webcasts.

Contact:

Evotec AG

Anne Hennecke

SVP, Investor Relations & Corporate Communications

Phone: +49-(0)40-56081-286

Fax: +49-(0)40-56081-333

E-Mail: anne.hennecke@evotec.com


'/>"/>
SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):